Suppr超能文献

慢性肾脏病对非 ST 段抬高型心肌梗死患者治疗过程和长期死亡率的影响:一项全国性队列研究和长期随访。

Impact of Chronic Kidney Disease on the Processes of Care and Long-Term Mortality of Non-ST-Segment-Elevation Myocardial Infarction: A Nationwide Cohort Study and Long-Term Follow-Up.

机构信息

Keele Cardiovascular Research Group, Centre for Prognosis Research Institute for Primary Care and Health Sciences, Keele University Keele Staffordshire United Kingdom.

Schulich Heart Program, Sunnybrook Health Sciences Centre University of Toronto, ICES Toronto Toronto Canada.

出版信息

J Am Heart Assoc. 2024 Aug 20;13(16):e032671. doi: 10.1161/JAHA.123.032671. Epub 2024 Aug 9.

Abstract

BACKGROUND

A growing population of patients with chronic kidney disease (CKD) presents with non-ST-segment-elevation myocardial infarction, although little is known about their longer-term mortality.

METHODS AND RESULTS

Using the MINAP (Myocardial Ischaemia National Audit Project) registry, linked to Office for National Statistics mortality data, we analyzed 363 559 UK patients with non-ST-segment-elevation myocardial infarction, with or without CKD. Cox regression models were fitted, adjusting for baseline demographics. Compared with patients without CKD, patients with CKD were less frequently prescribed P2Y12 inhibitors (89% versus 86%, <0.001) less likely to undergo invasive angiography (67% versus 41%, <0.001) or percutaneous coronary intervention (41% versus 25%, <0.001), and were less often referred to cardiac rehabilitation (80% versus 66%, <0.001). Following non-ST-segment-elevation myocardial infarction, patients with CKD had higher risk of 30-day (adjusted hazard ratio [HR], 1.24 [95% CI, 1.20-1.29], 1-year 1.47 [95% CI, 1.44-1.51]) and 5-year mortality 1.55 (95% CI, 1.53-1.58) than patients without CKD (all <0.001). Risk of mortality over the entire study period was highest in CKD Stage 5 (HR, 2.98 [95% CI, 2.87-3.10]), even after excluding mortality ≤30 days (HR, 3.03 [95% CI, 2.90-3.17]) (<0.001). There was no significant difference in proportion of deaths attributable to cardiovascular disease at 30 days (CKD; 76% versus no CKD; 76%), or 1 -year (CKD; 62% versus no CKD; 62%).

CONCLUSIONS

Patients with CKD were significantly less likely to receive invasive investigation or undergo percutaneous coronary intervention and had significantly higher risk of short- and longer-term mortality. Risk of mortality increased with reducing CKD stage. Cardiovascular disease was the main cause of mortality in patients with CKD, but at comparable rates to the general population with non-ST-segment-elevation myocardial infarction.

摘要

背景

患有慢性肾脏病(CKD)的患者数量不断增加,出现非 ST 段抬高型心肌梗死,但对于他们的长期死亡率知之甚少。

方法和结果

利用 MINAP(心肌缺血国家审计项目)登记处,并与国家统计局的死亡率数据相关联,我们分析了 363559 名患有非 ST 段抬高型心肌梗死的英国患者,包括有或没有 CKD 的患者。使用 Cox 回归模型,根据基线人口统计学数据进行调整。与没有 CKD 的患者相比,CKD 患者接受 P2Y12 抑制剂治疗的比例较低(89%比 86%,<0.001),接受血管造影(67%比 41%,<0.001)或经皮冠状动脉介入治疗(41%比 25%,<0.001)的可能性较低,接受心脏康复治疗的比例也较低(80%比 66%,<0.001)。非 ST 段抬高型心肌梗死后,CKD 患者 30 天(校正后的危险比[HR],1.24[95%CI,1.20-1.29])、1 年(1.47[95%CI,1.44-1.51])和 5 年死亡率(1.55[95%CI,1.53-1.58])的风险均高于没有 CKD 的患者(均<0.001)。在整个研究期间,CKD 第 5 期(HR,2.98[95%CI,2.87-3.10])患者的死亡率风险最高,甚至在排除 30 天内死亡(HR,3.03[95%CI,2.90-3.17])后也是如此(<0.001)。在 30 天(CKD:76%,无 CKD:76%)或 1 年(CKD:62%,无 CKD:62%)时,心血管疾病导致的死亡比例无显著差异。

结论

患有 CKD 的患者接受有创检查或经皮冠状动脉介入治疗的可能性明显较低,短期和长期死亡率明显较高。随着 CKD 阶段的降低,死亡率风险增加。心血管疾病是 CKD 患者死亡的主要原因,但与非 ST 段抬高型心肌梗死的一般人群相比,其死亡率相似。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/869e/11963930/f5c11749dafa/JAH3-13-e032671-g003.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验